Clinical Research Scientist
Focuses on the design of clinical studies within the clinical development programme.
Prior to joining COMPASS, Faith worked at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London and Imperial College London, where she gained 8 years’ experience designing, leading and analysing clinical studies in psychiatry, psychopharmacology and clinical neuroscience, alongside international academic and industrial collaborators. Faith completed a Mental Health Studies MSc and a Clinical Neurosciences PhD at the Institute of Psychiatry, Psychology, and Neuroscience at King’s College London, where her doctoral work was recognised to be one of the most significant contributions to psychiatry within the last decade by Faculty 1000, and her innovative research has been awarded numerous prizes from the Wellcome Trust, Engineering and Physical Sciences Research Council, and the British Association of Psychopharmacology.
Faith’s research has primarily aimed to identify novel biomarkers associated with mental health conditions, and whether these biomarkers can be modulated using novel pharmaceutical compounds, as determined by multi-modal neuroimaging techniques (PET, 1H-MRS, MRI, and fMRI). Her previous work specifically aimed to investigate molecular changes underlying behavioural and neural alterations in schizophrenia and depression, with a focus on the cannabinoid 1 receptor (CB1R), N-methyl-D-aspartate receptor (NMDAR), α5-GABAA receptor, pre-synaptic dopamine synthesis capacity and glutamatergic signalling.